Abstract

For decades, experts have endorsed the inclusion of low-dose aminoglycosides (AGs) in initial treatment for patients with Staphylococcus aureus bacteremia, especially when endocarditis is suspected. This practice made sense in light of strong in vitro evidence of antibiotic synergy and clinical data that showed that bacteremias cleared faster with two drugs; …

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call